Exagen Inc. (NYSE:XGN) – Investment analysts at Cantor Fitzgerald issued their FY2019 EPS estimates for shares of Exagen in a research note issued on Thursday, October 17th. Cantor Fitzgerald analyst C. Bijou forecasts that the company will earn ($1.63) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $18.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Exagen’s FY2020 earnings at ($1.23) EPS.
XGN has been the subject of a number of other research reports. William Blair initiated coverage on Exagen in a research report on Monday, October 14th. They set an “outperform” rating for the company. Cowen initiated coverage on Exagen in a research report on Monday, October 14th. They set an “outperform” rating and a $17.00 price target for the company.
Shares of XGN stock opened at $14.18 on Monday. Exagen has a 1-year low of $11.54 and a 1-year high of $19.50.
In other news, major shareholder Bio-Exagen L.P. H.I.G. purchased 859,897 shares of the stock in a transaction on Thursday, September 19th. The stock was bought at an average price of $17.24 per share, with a total value of $14,824,624.28.
Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.
See Also: How to Use a Moving Average for Trading
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.